Filter by: patients
Home > Community Treatment Reports and Side Effects > Zemplar Treatment Report
What is Zemplar?

Zemplar® is a brand name for the drug paricalcitol, a Vitamin D analog. It is used for the prevention and treatment of hyperparathyroidism associated with chronic kidney disease.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Hyperparathyroidism 5 1 Efficacy_cant_tell
Kidney Failure 2 0
Hypercalcemia (elevated calcium) 2 0
Treat side effects of another treatment 1 0

See all 10 patients currently taking Zemplar

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 0
Moderate
 0
Mild
 0
None
 1

Reported Dosages

  3 mcg weekly 1 mcg daily 2 mcg daily 4 mcg daily
  1 Number of Patients: 1 6 Number of Patients: 6 3 Number of Patients: 3 1 Number of Patients: 1  

Reported Stop Reasons

Why Patients Stopped Taking Zemplar (multiple reasons could be selected)
Reason # Patients Percentage of patients
Course of treatment ended 1   Course of treatment ended: 100%

See all 1 patient who’ve stopped taking Zemplar

Reported Duration See details about how long patients take this treatment ▼

Currently Taking Zemplar

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0

Stopped Taking Zemplar

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of Zemplar

Always
 0 0%
Usually
 1 100%
Sometimes
 0 0%
Never
 0 0%

Burden

Difficulty being on treatment

Burden of Zemplar

Very
 0 0%
Somewhat
 0 0%
A little
 1 100%
Not at all
 0 0%

Cost

Paid out of pocket

Cost of Zemplar

$200+
 0 0%
$100-199
 0 0%
$50-99
 0 0%
$25-49
 0 0%
< $25
 1 100%

See more information, including instructions, precautions, side effects, and interactions.

Report created on February 12, 2012.